{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T23:12:08Z","timestamp":1772838728291,"version":"3.50.1"},"reference-count":69,"publisher":"Informa UK Limited","issue":"2","funder":[{"name":"Andrew Kerr of Medical Expressions"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Microbiol."],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.2217\/fmb-2018-0233","type":"journal-article","created":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T12:18:31Z","timestamp":1543580311000},"page":"89-110","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["Glecaprevir\/Pibrentasvir for the Treatment of Chronic Hepatitis C Virus Infection"],"prefix":"10.1080","volume":"14","author":[{"given":"Federico J","family":"Mensa","sequence":"first","affiliation":[{"name":"Department of Clinical Development Infectious Diseases,AbbVie Inc.,\rNorth Chicago,\rIL\r60064,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Lovell","sequence":"additional","affiliation":[{"name":"Department of Statistics,AbbVie Inc.,\rNorth Chicago,\rIL\r60064,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tami","family":"Pilot-Matias","sequence":"additional","affiliation":[{"name":"Department of Clinical Virology,AbbVie Inc.,\rNorth Chicago,\rIL\r60064,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacokinetics,AbbVie Inc.,\rNorth Chicago,\rIL\r60064,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,11,30]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27259"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30181-9"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.10.023"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.6502"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03587.x"},{"key":"e_1_3_3_8_1","unstructured":"AASLD and IDSA . HCV guidance: recommendations for testing managing and treating hepatitis C ( 2017 ). www.hcvguidelines.org"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.026"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.08.043"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.6"},{"key":"e_1_3_3_12_1","unstructured":"WHO . Global health sectors strategy on viral hepatitis 2016\u20132021: towards ending viral hepatitis ( 2016 ). http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/246177\/WHO-HIV-2016.06-eng.pdf;jsessionid=C1D2C4268A94C9FFE3D529FFA3871943?sequence=1"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ197"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.20.1.22146"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.106"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis928"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9680-7"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004151"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30406-3"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000903"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(18)30798-0"},{"key":"e_1_3_3_22_1","unstructured":"AbbVie . Mavyret US prescribing information ( 2017 ). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209394s003lbl.pdf"},{"key":"e_1_3_3_23_1","unstructured":"AbbVie . Maviret EU summary of product characteristics ( 2018 ). www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR__Product_Information\/human\/004430\/WC500233677.pdf"},{"key":"e_1_3_3_24_1","unstructured":"AbbVie . Maviret Health Canada product monograph ( 2017 ). https:\/\/pdf.hres.ca\/dpd_pm\/00040732.PDF"},{"key":"e_1_3_3_25_1","unstructured":"AbbVie . Maviret Japan prescribing information ( 2017 ). www.abbvie.co.jp\/content\/dam\/abbviecorp\/japan\/docs\/Maviret_tmpDocument.pdf"},{"key":"e_1_3_3_26_1","unstructured":"Gilead Sciences . Vosevi EU summary of product characteristics ( 2017 ). www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR__Product_Information\/human\/004350\/WC500235373.pdf"},{"key":"e_1_3_3_27_1","unstructured":"Gilead Sciences . Vosevi US prescribing information ( 2017 ). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209195s002lbl.pdf"},{"key":"e_1_3_3_28_1","unstructured":"Gilead Sciences . Vosevi Health Canada product monograph ( 2017 ). https:\/\/pdf.hres.ca\/dpd_pm\/00040726.PDF"},{"key":"e_1_3_3_29_1","unstructured":"Gilead Sciences . Epclusa EU summary of product characteristics ( 2017 ). www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR__Product_Information\/human\/004210\/WC500211151.pdf"},{"key":"e_1_3_3_30_1","unstructured":"Gilead Sciences . Epclusa US prescribing information ( 2017 ). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208341s009lbl.pdf"},{"key":"e_1_3_3_31_1","unstructured":"Gilead Sciences . Epclusa Health Canada product monograph ( 2017 ). https:\/\/pdf.hres.ca\/dpd_pm\/00041214.PDF"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512610"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.032"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01620-17"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.07.035"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02558-16"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.12.015"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2016.10.007"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.350"},{"key":"e_1_3_3_41_1","first-page":"641A","article-title":"Glecaprevir and pibrentasvir exposures in hepatits C virus-infected subjects in Phase 2 and 3 studies (abstract and poster 1190)","volume":"66","author":"Lin CW","year":"2017","unstructured":"Lin CW , EckertD , MensingS , LiuW . Glecaprevir and pibrentasvir exposures in hepatits C virus-infected subjects in Phase 2 and 3 studies (abstract and poster 1190) . Hepatology66 , 641A ( 2017 ).","journal-title":"Hepatology"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.959"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30930-3"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(16)00644-9"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01990-17"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.039"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.07.020"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29081"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702417"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.09.027"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29541"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30496-6"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29671"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30467-1"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704053"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30444-0"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(18)30265-4"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.007"},{"issue":"1","key":"e_1_3_3_59_1","first-page":"A35","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in treatment-naive patients with chronic HCV genotype 3: an integrated Phase 2\/3 analysis (abstract 62 and oral presentation)","volume":"66","author":"Flamm S","year":"2017","unstructured":"Flamm S , WylesD , AsatryanAet al. Efficacy and safety of glecaprevir\/pibrentasvir in treatment-naive patients with chronic HCV genotype 3: an integrated Phase 2\/3 analysis (abstract 62 and oral presentation) . Hepatology66 ( Suppl. 1 ), A35 ( 2017 ).","journal-title":"Hepatology"},{"key":"e_1_3_3_60_1","first-page":"A44","article-title":"Efficacy, safety, and pharmacokinetics of glecaprevir\/pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infection and compensated cirrhosis: an integrated analysis (abstract and oral 74)","volume":"66","author":"Gane E","year":"2017","unstructured":"Gane E , PoordadF , ZadeikisNet al. Efficacy, safety, and pharmacokinetics of glecaprevir\/pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infection and compensated cirrhosis: an integrated analysis (abstract and oral 74) . Hepatology66 , A44 ( 2017 ).","journal-title":"Hepatology"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)31967-0"},{"key":"e_1_3_3_62_1","first-page":"A636","article-title":"Safety and efficacy of glecaprevir\/pibrentasvir in patients with chronic hepatitis C genotypes 1\u20136 and recent drug use (abstract and poster 1182)","volume":"66","author":"Foster GR","year":"2017","unstructured":"Foster GR , GrebelyJ , ShermanKEet al. Safety and efficacy of glecaprevir\/pibrentasvir in patients with chronic hepatitis C genotypes 1\u20136 and recent drug use (abstract and poster 1182) . Hepatology66 , A636 ( 2017 ).","journal-title":"Hepatology"},{"key":"e_1_3_3_63_1","first-page":"A640","article-title":"Safety and efficacy of glecaprevir\/pibrentasvir in patients aged 65 years or older with chronic hepatitis C: a pooled analysis of Phase 2 and 3 clinical trials (abstract and poster 1188)","volume":"66","author":"Foster GR","year":"2017","unstructured":"Foster GR , Kopecky-BrombergS , LeiY , MensaFJ . Safety and efficacy of glecaprevir\/pibrentasvir in patients aged 65 years or older with chronic hepatitis C: a pooled analysis of Phase 2 and 3 clinical trials (abstract and poster 1188) . Hepatology66 , A640 ( 2017 ).","journal-title":"Hepatology"},{"key":"e_1_3_3_64_1","volume-title":"World Congress of Gastroenterology at ACG 2017.","author":"Flamm S","year":"2017","unstructured":"Flamm S , ReddyR , ZadeikisNet al. Integrated efficacy, pharmacokinetics, and safety of glecaprevir\/pibrentasvir in patients taking concomitant proton pump inhibitors and other acid-reducing drugs . Presented at : World Congress of Gastroenterology at ACG 2017.Orlando, FL, USA , 13\u201318 October2017 ."},{"key":"e_1_3_3_65_1","volume-title":"American College of Cardiology 2018.","author":"Kwo PY","year":"2018","unstructured":"Kwo PY , JonesPH , BarcombLet al. Safety and efficacy of statin management during glecaprevir\/pibrentasvir treatment for chronic hepatitis C . Presented at : American College of Cardiology 2018.Orlando, FL, USA , 10\u201312 March2018 ."},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)31399-5"},{"key":"e_1_3_3_67_1","first-page":"A114","article-title":"Adherence to pangenotypic glecaprevir\/pibrentasvir treatment and SVR12 in HCV-infected patients: an integrated analysis of the Phase 2\/3 clinical trial program (abstract and oral 198)","volume":"66","author":"Brown A","year":"2017","unstructured":"Brown A , WelzelTM , ConwayBet al. Adherence to pangenotypic glecaprevir\/pibrentasvir treatment and SVR12 in HCV-infected patients: an integrated analysis of the Phase 2\/3 clinical trial program (abstract and oral 198) . Hepatology66 , A114 ( 2017 ).","journal-title":"Hepatology"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)31432-0"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(18)30351-9"},{"key":"e_1_3_3_70_1","volume-title":"16th Annual International Symposium on Viral Hepatitis and Liver Disease\u2019s Global Hepatitis Summit 2018.","author":"Cornberg M","year":"2018","unstructured":"Cornberg M , NaumannU , StoehrAet al. Real-world data on safety and effectiveness of glecaprevir\/pibrentasvir for the treatment of patients with chronic hepatitis C virus infection: latest results from the German Hepatitis C-Registry . Presented at : 16th Annual International Symposium on Viral Hepatitis and Liver Disease\u2019s Global Hepatitis Summit 2018.Toronto, Ontario, Canada , 14\u201317 June2018 ."},{"key":"e_1_3_3_71_1","unstructured":"EMA . Maviret EPAR Assessment Report . ( 2017 ). www.ema.europa.eu\/documents\/assessment-report\/maviret-epar-public-assessment-report_en.pdf"}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fmb-2018-0233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:40:59Z","timestamp":1719124859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fmb-2018-0233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.2217\/fmb-2018-0233"],"URL":"https:\/\/doi.org\/10.2217\/fmb-2018-0233","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"value":"1746-0913","type":"print"},{"value":"1746-0921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-08-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}